Puccetti 2001.

Methods	6‐week dietary period 6‐week before‐and‐after study
Participants	25 men and women with primary hypercholesterolaemia mean age 48.2 received cerivastatin TC 6.93 mmol/L (268 mg/dL), HDL‐C 1.25 mmol/L (48.3 mg/dL) and TG 1.15 mmol/L (102 mg/dL) Exclusion criteria: history of cardiovascular events or current hypertension, diabetes, or liver, renal, thyroid, infectious, immunological or malignant diseases. None of the participants had a personal or family history of deep vein thrombosis or a tendency to bleed, an none of them were taking hypolipidaemic, antiplatelet, anticoagulant or profibrinolytic drugs Cerivastatin 0.2 mg/d baseline TC: 6.62 mmol/L (256 mg/dL) Cerivastatin 0.2 mg/d baseline LDL‐C: 4.89 mmol/L (189.1 mg/dL) Cerivastatin 0.2 mg/d baseline HDL‐C: 1.24 mmol/L (47.9 mg/dL) Cerivastatin 0.2 mg/d baseline TG: 1.05 mmol/L (93 mg/dL)
Interventions	Cerivastatin 0.2 mg/d Atorvastatin 10 mg/d Simvastatin 20 mg/d Pravastatin 20 mg/d Fluvastatin 20 mg/d
Outcomes	Percentage change from baseline at 6 weeks of plasma TC, LDL‐C, HDL‐C and TG
Source of funding	University of Siena
Notes	Atorvastatin 10 mg/d, simvastatin 20 mg/d, pravastatin 20 mg/d and fluvastatin 20 mg/d data were not analysed. SDs were imputed by the method of Furukawa 2006
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Controlled before‐and‐after design
Allocation concealment (selection bias)	High risk	Controlled before‐and‐after design
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) LDL‐C	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAE	High risk	No comparison possible
Incomplete outcome data (attrition bias) Total cholesterol	Low risk	All participants were included in the efficacy analysis
Incomplete outcome data (attrition bias) LDL cholesterol	Low risk	All participants were included in the efficacy analysis
Incomplete outcome data (attrition bias) HDL cholesterol	Low risk	All participants were included in the efficacy analysis
Incomplete outcome data (attrition bias) Triglycerides	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Low risk	Work funded by University of Siena